SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission

Conditions:Blood Cancer, Blood Cancer, Hematology
Therapuetic Areas:Hematology, Oncology
Age Range:18 - Any
Start Date:February 2015
End Date:December 2019
Contact:Shay Shemesh

Use our guide to learn which trials are right for you!

A Phase 1/2 Study of SL-401 as Consolidation Therapy for Adult Patients With Adverse Risk Acute Myeloid Leukemia in First CR, and/or Evidence of Minimal Residual Disease (MRD) in First CR

This is a non-randomized open label multi-center study. Patients who are in their first
complete remission (CR) following induction therapy will be treated with SL-401, which will
be administered as a brief intravenous infusion for 5 consecutive days every 28 days for 6 or
more cycles. Stage 1 will consist of a period in which approximately 6-9 patients will be
treated with SL-401 at 3 dose levels. During Stage 2, up to approximately 20 patients with
minimal residual disease (MRD) in their bone marrow will be treated at a maximum tolerated
dose or maximum tested dose in which multiple dose-limiting toxicities are not observed
(identified in Stage 1).

Inclusion Criteria:

1. The patient has a diagnosis of AML according to World Health Organization (WHO)

2. The patient received any induction chemotherapy regimen and may have received
post-remission consolidation therapy prior to screening.

3. The patient has achieved a first or second CR or CRi. For patients without evidence of
MRD in CR/CRi, CR (or CRi) must have been initially identified within 12 months prior
to screening.

OR The patient has achieved first or second CR or CRi with evidence of MRD as
determined locally at least 6 months post stem cell transplant without evidence of
acute or chronic graft-versus-host disease post-transplant and has not received
immunosuppressant therapy for at least 14 days prior to SL-401 therapy.

4. The patient has adverse risk disease or AML for which there is otherwise a substantial
risk of relapse, which includes but is not limited to: adverse karyotype, FLT3
internal tandem duplication (ITD) mutation, history of antecedent hematologic disorder
(AHD), therapy-related AML, history of requiring more than 1 cycle of intensive
induction chemotherapy to achieve first remission, and/or presence of persistent MRD
(detected by cytogenetics, molecular markers, or flow cytometry) at any point after
the initial induction cycle.

5. For patients enrolling in Stage 2, the bone marrow evaluation determined locally
within the previous 6 months indicates the presence of MRD.

6. The patient is not considered to be an immediate candidate for allogeneic stem cell
transplant as determined by the investigator.

7. The patient is ≥18 years old.

8. The patient has an Eastern Cooperative Oncology Group (ECOG) performance score (PS) of

9. The patient has adequate organ function, including cardiac, renal, and hepatic

- Left ventricular ejection fraction (LVEF) ≥institutional lower limit of normal as
measured by multigated acquisition scan (MUGA) or 2-dimensional (2-D)
echocardiography (ECHO) within 28 days prior to start of therapy and no
clinically significant abnormalities on a 12-lead electrocardiogram (ECG)

- Serum creatinine ≤1.5 mg/dL

- Serum albumin ≥3.2 g/dL in the absence of receipt of (IV) albumin within the
previous 72 hours.

- Bilirubin ≤1.5 mg/dL

- Aspartate transaminase (AST) and alanine transaminase (ALT) ≤2.5 × the upper
limit of normal (ULN)

- Creatine phosphokinase (CPK) ≤2.5 × the ULN.

10. The patient has adequate bone marrow reserve:

• Absolute neutrophil count (ANC) > 0.5 × 10^9/L

11. The patient is a woman of child bearing potential (WOCBP) who has had a negative serum
or urine pregnancy test within 1 week prior to SL-401 treatment (intervals shorter
than 1 week are acceptable if required by institutional guidelines).

12. A written and voluntarily signed informed consent must be obtained from the patient or
legally authorized representative, in accordance with local regulations, before the
initiation of any study related procedures. The patient or legally authorized
representative must be able to read and understand the informed consent form (ICF).

13. The patient is able to adhere to the study visit schedule and other protocol
requirements, including follow-up for survival assessment.

14. The patient (male and female) agrees to use acceptable contraceptive methods for the
duration of time on the study, and continue to use acceptable contraceptive methods
for 2 months after the last infusion of SL-401.

Exclusion Criteria:

1. The patient has a diagnosis of AML associated with karyotype t(15;17).

2. The patient has persistent and clinically significant Grade ≥2 toxicities from
induction or consolidation therapy (excluding alopecia, nausea, fatigue, and liver
function tests [as mandated in the inclusion criteria]) not readily managed with
supportive measures.

3. The patient received treatment with another investigational agent within 14 days of

4. The patient previously received treatment with SL-401.

5. The patient has an active malignancy and/or cancer history (excluding AML or
antecedent myelodysplastic syndrome [MDS]) that may confound the assessment of the
study endpoints. Patients with a past cancer history (within 2 years of entry) with
substantial potential for recurrence and/or ongoing active malignancy must be
discussed with the Sponsor before study entry. Patients with the following neoplastic
diagnoses are eligible: non-melanoma skin cancer, carcinoma in situ (including
superficial transitional cell carcinoma of the bladder), cervical intraepithelial
neoplasia, organ-confined prostate cancer with no evidence of progressive disease.

6. The patient has clinically significant cardiovascular disease (e.g., uncontrolled or
any New York Heart Association [NYHA] Class 3 or 4 congestive heart failure,
uncontrolled angina, history of myocardial infarction, unstable angina or stroke
within 6 months prior to study entry, uncontrolled hypertension or clinically
significant arrhythmias not controlled by medication).

7. The patient has uncontrolled, clinically significant pulmonary disease (e.g., chronic
obstructive pulmonary disease, pulmonary hypertension) that in the opinion of the
Investigator would put the patient at significant risk for pulmonary complications
during the study.

8. The patient has known active or suspected central nervous system (CNS) leukemia. If
suspected, CNS leukemia should be ruled out with relevant imaging and/or examination
of cerebrospinal fluid.

9. The patient has uncontrolled intercurrent illness including, but not limited to,
uncontrolled infection, disseminated intravascular coagulation (DIC), or psychiatric
illness/social situations that would limit compliance with study requirements.

10. The patient is pregnant or breast feeding.

11. The patient has known positive status for human immunodeficiency virus (HIV), active
or chronic Hepatitis B or Hepatitis C.

12. The patient is oxygen-dependent.

13. The patient has any medical condition which in the opinion of the Investigator places
the patient at an unacceptably high risk for toxicities.
We found this trial at
500 S State St
Ann Arbor, Michigan 48109
(734) 764-1817
Principal Investigator: Dale Bixby, M.D.
Phone: 734-615-1482
University of Michigan The University of Michigan was founded in 1817 as one of the...
Ann Arbor, MI
Click here to add this to my saved trials
12902 USF Magnolia Dr
Tampa, Florida 33612
(888) 663-3488
Principal Investigator: Kendra Sweet, M.D.
Phone: 888-663-3488
H. Lee Moffitt Cancer Center & Research Institute Moffitt Cancer Center in Tampa, Florida, has...
Tampa, FL
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
Principal Investigator: Andrew Lane, M.D.
Phone: 617-632-4589
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Boston, MA
Click here to add this to my saved trials
1300 Morris Park Ave
Bronx, New York 10461
(718) 430-2000
Principal Investigator: Ioannis Mantzaris, M.D.
Phone: 718-920-4826
Albert Einstein College of Medicine The Albert Einstein College of Medicine of Yeshiva University is...
Bronx, NY
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Marina Konopleva, M.D.
Phone: 713-792-2121
Houston, TX
Click here to add this to my saved trials
250 25th Ave N, Ste 100
Nashville, Tennessee 37023
Principal Investigator: William Donnellan, M.D.
Phone: 615-956-7600
Tennessee Oncology, PLLC Since 1976 Tennessee Oncology has been providing quality cancer care. In 2013,...
Nashville, TN
Click here to add this to my saved trials
Seattle, Washington 98109
Principal Investigator: Roland Walter, M.D.
Phone: 206-667-3599
Seattle, WA
Click here to add this to my saved trials